Cell and gene therapies require highly coordinated supply chains because manufacturing often involves patient-specific materials, strict temperature requirements, complex scheduling and detailed chain-of-identity tracking. These requirements are creating demand for digital platforms designed specifically for advanced therapy logistics.
The cell and gene therapy supply chain software market is estimated at approximately USD 356 million in 2026 and is expected to grow at a CAGR of 15.8% through 2035.
Unlike conventional pharmaceutical supply chains, cell and gene therapy workflows can involve the collection of biological material from an individual patient, transportation to a manufacturing facility, processing, storage and return shipment for administration. Each step needs accurate tracking and coordination.
Software platforms can help manage patient scheduling, inventory, transportation, manufacturing milestones and delivery information. Digital traceability is particularly important because errors in patient identification or material handling can have serious consequences.
The market is also benefiting from increasing globalization of advanced therapy development. Developers and manufacturers are increasingly working across multiple regions, creating additional logistical and regulatory complexity.
In April 2026, Andelyn Biosciences collaborated with ENCell to create a US-APAC gene therapy manufacturing corridor, highlighting the growing need for coordinated international supply-chain infrastructure.
Software providers are responding by expanding integrations, automation and real-time visibility. Companies such as Azenta Life Sciences, BioLife Solutions, Cryoport, Lonza, TraceLink, TrakCel and Veeva Systems are among the players active in this ecosystem.
As more cell and gene therapies progress through clinical development and commercialization, supply-chain software is likely to become an increasingly important part of advanced therapy infrastructure.
For more information on the Cell and Gene Therapy Supply Chain Software Market, visit:
https://www.rootsanalysis.com/reports/cell-therapies-supply-chain/260.html
Comments